Spirogen is a clinical stage biotechnology company specialising in novel, sequence-selective, DNA minor groove-binding molecules with potent therapeutic properties. Spirogen's principal technology involves modification of members of a group of naturally occurring antibiotics called pyrrolobenzodiazepines (PBDs). The company was founded in 2000, has 18 employees and is private equity funded.
Spirogen’s lead oncology drug candidate, SG2000, has completed solid tumour Phase I studies in the USA (through the NCI) and Europe (through Cancer Research UK). A Phase II study in cisplatin refractory ovarian cancer is underway in the USA, and a haematological Phase II study is planned in Europe for early 2012.
Currently, Spirogen’s pipeline comprises two well characterized DNA minor-groove binding, interstrand cross-linking PBD dimer molecules, SG2000 and SG2285, plus a number of earlier stage leads. Additionally, the achiral duocarmycin analogue, AS-1-145 (Centanamycin), is now in pre-clinical development with the NCI.
A number of Spirogen’s highly potent antineoplastic molecules are under development and evaluation with pharmaceutical companies as candidates for development as warheads in antibody drug conjugate (ADC) therapies. Spirogen also has its own active program of ADC warhead and linker development. Spirogen also works closely with ADC Therapeutics sarl in the development of its ADCs.
Please visit our History page for a brief summary of some of the key corporate milestones in Spirogen’s history.